Christie’s Global Auction Channel Sales Total £3.9 Billion/US$5.0 Billion In 2019
21.12.2019 02:17:00 EET | Business Wire | Press release
Christie’s announced auction channel sales of £3.9 billion (US$5 billion) for 2019.
Key highlights for the year included:
- A new top price for any living artist at auction, achieved with Jeff Koon’s Rabbit, which realized US$91,075,000 at Christie’s New York in May 2019.
- Numerous record prices in 2019, including top prices for artworks and objects sold in London (David Hockney, Henry Geldzahler and Christopher Scott, for £37,661,248/US$49,521,696), Hong Kong (Sanyu, Five Nudes, for HK$303,984,992/US$38,848,420) and Geneva (Patek Philippe Grandmaster Chime ref. 6300A for ONLY WATCH for CHF31,000,000/US$31,244,094). In Paris Nicolas de Staël’s Parc des Princes realized €20,000,000/US$22,254,368, and set a record for the artist and was the top price for any lot sold at Christie’s Paris this year.
- Christie’s remained the auction house of choice for major private and estate collections, achieving the top three results for named collections in 2019 with Masterpieces from the Collection of S.I. Newhouse, The Robert B. and Beatrice C. Mayer Family Collection, and Maharajas and Mughal Magnificence.
- Strong results were also achieved for the collections of notable collectors David Gilmour, Drue Heinz, the Irving Collection, James and Marilynn Alsdorf, Terry Allen Kramer, Eileen and I.M. Pei, Richard L. Weisman, George Michael, the Clarke Collection, Ron and Diane Disney Miller, the Matthys-Colle Collection, works from the UniCredit Group, Jeremy Lancaster, and masterpieces from a Rothschild Collection.
Guillaume Cerutti, Chief Executive Officer, commented: “Amid a challenging global environment, demand for art remains strong and is reflected in our 2019 results, especially for Modern and Contemporary art. In the last month alone, we were particularly pleased by the results achieved in New York for Christie’s 20th Century Art week, in Hong Kong for our Autumn sale series—despite a heightened political context—and in London during our Classic Week sales, including Old Masters. We are looking forward to continuing the momentum in 2020.”
For more on Christie’s top 2019 moments, please visit our online feature here.
Christie’s will publish full 2019 results, inclusive of private and e-commerce channel sales, in early 2020.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191220005580/en/
Contact information
PRESS:
Nicky Eaton
London | presslondon@christies.com
New York | communicationsamericas@christies.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Serbian Biotech Startup Takes Its Journey from Belgrade to Cambridge with Documentary on Longevity Science21.9.2026 14:02:00 EEST | Press release
BioEridan, a Serbian biotechnology startup backed by Telekom Srbija Group’s TS Ventures Fund, has premiered a new documentary showcasing its development of underwater Aquafarms and its ambition to contribute to the next generation of longevity science. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260921345879/en/ BioEridan Documentary Premiere BioEridan: Science Beneath the Surface premiered in Belgrade on September 15 before being screened the following day at a UK-Serbia Health, Digital Transformation & Innovation roundtable held at Christ’s College, University of Cambridge, as part of Cambridge Tech Week 2026. The roundtable brought together prominent representatives from the UK and Serbia across science, healthcare, technology, academia and business to discuss opportunities for collaboration, innovation and the commercialisation of scientific research. The documentary follows BioEridan’s development from an early scien
LabVantage Named a Visionary Leader in Life Sciences and Industrial LIMS by Frost & Sullivan21.9.2026 11:30:00 EEST | Press release
LabVantage Solutions, Inc., a leading global provider of laboratory informatics solutions and services, has been named a Visionary Leader in two 2026 Frost Radar™ reports by Frost & Sullivan: Frost Radar™: Life Sciences Laboratory Information Management Systems, 2026 and Frost Radar™: Laboratory Information Management Systems in Industrial Applications, 2026. Announced at LabVantage’s Customer Training and Education Conference (CTEC) Europe 2026 in Paris, the dual recognition marks LabVantage’s fourth consecutive year of Frost Radar leadership. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260921487430/en/ The Frost Radar is an independent benchmarking analysis that evaluates companies on a Growth Index and an Innovation Index. The Growth Index measures a company’s growth performance, track record, and ability to execute its growth strategy, while the Innovation Index assesses its ability to develop globally applicable solu
Bending Spoons opens office in Warsaw as Polish applications reach 50,000 in 202621.9.2026 10:15:00 EEST | Press release
Bending Spoons has opened an office in Warsaw, adding to its Milan headquarters and locations in London and Madrid. The technology company, whose portfolio includes Eventbrite and WeTransfer, has seen a sharp rise in applications from Poland and will use the new base to recruit locally for roles across key projects. “We’ve received around 50,000 applications from Poland so far this year, more than twice as many as the whole of 2025. What stands out isn’t just the volume. Many Polish candidates are among the strongest we see in our selection process, and the student talent has been particularly impressive. More than half of our recent hires from Poland were still studying when they applied,” says Andrea Maiorana, Talent data lead. Located in Śródmieście, Warsaw’s city center, the office is within walking distance of the Presidential Palace and the University of Warsaw. Bending Spoons encourages all new hires to spend their first few months in Milan, with travel and accommodation costs f
Strongest Half-Year in Curatis’s History — Revenue up 51% and Significant Progress on Corticorelin (C-PTBE-01)21.9.2026 08:03:00 EEST | Press release
Curatis Holding AG (SIX:CURN, “Curatis”) reports net sales from goods and services of CHF 7.9m for the first half of 2026, up 51% (H1 2025: CHF 5.2m), with the loss for the period narrowing to CHF -0.4m (H1 2025: CHF -1.2m) and cash and cash equivalents rising to CHF 3.6m (31 December 2025: CHF 1.9m). Curatis also advanced its corticorelin (C-PTBE-01) program on multiple levels, including an exclusive Japan licence with Neupharma and continued manufacturing progress. Business development and finances Net sales from goods increased by 46% to CHF 7.4m (H1 2025: CHF 5.0m) and net sales from services rose to CHF 0.6m (H1 2025: CHF 0.2m). Growth was driven both by products marketed for some time and by products added to the distribution portfolio in 2025 and 2026. The gross contribution from goods and services rose by 32% to CHF 1.8m (H1 2025: CHF 1.3m); the combined cost base grew by only 9% against net sales growth of 51%, as personnel expenses rose 5% to CHF 1.3m (H1 2025: CHF 1.2m) and
Galderma Begins Trading in the Swiss Market Index, Joining Switzerland's Leading Blue Chip Companies21.9.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today begins trading as a constituent of the Swiss Market Index (SMI), Switzerland's leading blue chip equity benchmark comprising 20 of the country's largest and most liquid listed companies. Less than three years after its IPO on the SIX Swiss Exchange in March 2024, Galderma has established itself as one of Switzerland's leading listed companies. Its inclusion in the SMI reflects the company's strong growth, disciplined execution and increasing relevance in Swiss and international capital markets as it advances its ambition to become the world's leading dermatology powerhouse. Since its IPO, Galderma has continued to execute its growth-focused integrated dermatology strategy, delivering strong performance across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Net sales increased from 4.410 billion USD in 2024 to 5.207 billion USD in 2025, driven by science-led innovation, portfolio and geogr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
